Science & Enterprise subscription

Follow us on Twitter

  • Then "Day at the Races"
    about 13 hours ago
  • The Forward, America’s Leading Jewish News Organization, Goes All Digital. Third-generation subscriber here and wor…
    about 15 hours ago
  • Our friends at Statista reported on a survey on how the shutdown is affecting people in the U.S., this weekend's in…
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Americans Affected by Gov’t Shutdown #Science #Business
    about 18 hours ago
  • New contributed post on Science and Enterprise: Hands Off! Robots in Modern Medicine
    about 19 hours ago

Please share Science & Enterprise

Follow by Email
Visit Us

Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug

Alectos Therapeutics Inc. in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company Merck & Co. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer’s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and commercialize compounds that modulate this target.

Under the agreement, Merck has paid Alectos for and will fund further research into Alectos’ existing portfolio of compounds targeting Alzheimer’s disease. Alectos is eligible for up to US $289 million in fees, research, development, and regulatory milestones and tiered royalty payments on sales of any products resulting from this collaboration.

Alectos and Merck will collaborate on drug discovery and preclinical development. Merck will handle clinical development and have worldwide marketing and commercialization rights to any resulting products.

Alectos Therapeutics is a spin-off biotechnology company from Simon Fraser University that develops small-molecule drugs for serious and life-threatening human diseases.

Please share Science & Enterprise ...

1 comment to Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug